AMRE 26.50 Amreit Inc $AMRE Hit a 52 week high of 26.50

New Post Public Reply Private Reply Replies (0) Message Board

Nov 8, 2014 at 10:38 PM

AMRE 26.50 Amreit Inc $AMRE Hit a 52 week high of 26.50 Currently at 26.50 +0.04 +0.15% With a day low of 26.34 and a total volume of 309,600.

AMRE Amreit Inc Recent Headline News

AMREIT, INC. INVESTOR ALERT: Faruqi & Faruqi, LLP Announces the Investigation of AmREIT, Inc. (AMRE) Over the Proposed Sale of the Company to Edens Investment Trust
PR Newswire - Thu Nov 06, 3:42PM CST
Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of AmREIT, Inc. ("AmREIT" or the "Company"

(NYSE:AMRE) for potential breaches of fiduciary duties in connection with the sale of the Company to Edens Investment Trust ("Edens"

for approximately $763 million. The Company's stockholders will receive $26.55 for each share of AmREIT common stock they own.
AMRE: 26.50 (+0.04)

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Initiates Investigation of the Board of Directors of AmREIT, Inc. in Connection With the Fairness of the Sale of the Company to Edens Investment Trust
Business Wire - Thu Nov 06, 2:48PM CST
Levi & Korsinsky is investigating the Board of Directors of AmREIT, Inc. ("AmREIT" or "the Company"

(NYSE:AMRE) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Edens Investment Trust.
AMRE: 26.50 (+0.04)

Robbins Arroyo LLP: Acquisition of AmREIT Inc. (AMRE) by Edens Investment Trust May Not Be in Shareholders' Best Interests
PR Newswire - Wed Nov 05, 7:10PM CST
Shareholder rights attorneys at Robbins Arroyo LLP are investigating the proposed acquisition of AmREIT Inc. (NYSE: AMRE) by Edens Investment Trust, a private company. On October 31, 2014, AmREIT announced the signing of a definitive merger agreement pursuant to which Edens will acquire all the outstanding shares of AmREIT for $26.55 per share in cash.
AMRE: 26.50 (+0.04)

SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of AmREIT, Inc. in Connection with the Sale of the Company
Business Wire - Wed Nov 05, 5:35PM CST
Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of AmREIT, Inc. ("AmREIT" or the "Company"

(NYSE: AMRE) relating to the proposed acquisition by Edens Investment Trust ("Edens"

.
AMRE: 26.50 (+0.04)

AMREIT, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout
PR Newswire - Wed Nov 05, 12:59PM CST
Rigrodsky & Long, P.A.:
AMRE: 26.50 (+0.04)

Lifshitz & Miller Law Firm Announces Investigation of AmREIT, Inc., Digital River, Inc., Greater Sacramento Bancorp., Hampden Bancorp, Inc., Integrity Bancshares, Inc., Retrophin, Inc. and Sapient Corp.
PR Newswire - Wed Nov 05, 11:33AM CST
AmREIT, Inc.
HBNK: 19.91 (+0.15), DRIV: 24.68 (+0.09), AMRE: 26.50 (+0.04), SAPE: 24.67 (+0.03), RTRX: 10.38 (+0.29)

AmREIT Shareholder Alert: Former SEC Attorney Willie Briscoe and Powers Taylor LLP Investigate Sale to Edens Investment Trust
Business Wire - Tue Nov 04, 10:56AM CST
Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board of Directors of AmREIT, Inc. ("AmREIT"

(NYSE: AMRE) concerning the acquisition by Edens Investment Trust. Under the terms of the agreement AmREIT shareholders will only receive $26.55 in cash per AmREIT share owned.
AMRE: 26.50 (+0.04)

EQUITY ALERT: The Rosen Law Firm Announces Investigation of AmREIT, Inc. Concerning its Proposed Sale to Edens Investment Trust - AMRE
Business Wire - Tue Nov 04, 10:55AM CST
The Rosen Law Firm, P.A. announces that it is investigating the Board of Directors of AmREIT, Inc. (NYSE: AMRE) for possible breaches of fiduciary duty and other violations of law by failing to adequately shop AmREIT to maximize shareholder value before agreeing to be acquired by Edens Investment Trust.
AMRE: 26.50 (+0.04)

AMRE INVESTOR ALERT: Levi & Korsinsky, LLP Launches Investigation into the Board of Directors of AmREIT, Inc. Regarding the Fairness of the Sale of the Company to Edens Investment Trust -- AMRE
PR Newswire - Tue Nov 04, 10:40AM CST
Levi & Korsinsky is investigating the Board of Directors of AmREIT, Inc. ("AmREIT" or "the Company"

(NYSE: AMRE) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Edens Investment Trust.
AMRE: 26.50 (+0.04)

AmREIT Reports Third Quarter Results and Declares December 2014 Dividend
Business Wire - Tue Nov 04, 7:31AM CST
AmREIT, Inc. (NYSE:AMRE) ("AmREIT" or the "Company"

today announced financial results for the third quarter ended September 30, 2014 and declared dividends for the fourth quarter ending December 31, 2014.
AMRE: 26.50 (+0.04)

SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of AmREIT, Inc. in Connection with the Sale of the Company -AMRE
PR Newswire - Mon Nov 03, 8:35PM CST
Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of AmREIT, Inc.. ("AmREIT" or the "Company"

(NYSE -AMRE-News) relating to the proposed acquisition by Edens Investment Trust. ("Edens"

.
AMRE: 26.50 (+0.04)

AmREIT INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of AmREIT, Inc.
PR Newswire - Mon Nov 03, 7:41PM CST
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF"

are investigating the proposed sale of AmREIT, Inc. ("AmREIT" or the "Company"

(NYSE: AMRE) to Edens Investment Trust. Under the terms of the proposed transaction, shareholders of AmREIT will receive only $26.55 in cash for each share of AmREIT common stock that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
AMRE: 26.50 (+0.04)

AmREIT signs definitive acquisition agreement with EDENS for USD763m total cash
M2 - Mon Nov 03, 7:27AM CST
AmREIT Inc (NYSE:AMRE), a real estate investment trust, revealed on Saturday that it has signed a definitive agreement with Edens Investment Trust (EDENS), under which all outstanding shares of AMREIT common stock will be bought for USD26.55 per share in an all-cash transaction by EDENS, with a total enterprise value of about USD763m.
AMRE: 26.50 (+0.04), REG: 61.54 (-0.36)

AmREIT to Be Acquired by EDENS for $26.55 Per Share
Business Wire - Fri Oct 31, 10:29PM CDT
AmREIT, Inc. (NYSE:AMRE) today announced that it has entered into a definitive agreement with Edens Investment Trust ("EDENS"

under which EDENS will acquire all outstanding shares of common stock of AmREIT for $26.55 per share in an all-cash transaction with a total enterprise value of approximately $763 million.
AMRE: 26.50 (+0.04), REG: 61.54 (-0.36)

AmREIT Expands Its Portfolio of Irreplaceable Corners in Atlanta with the Acquisition of Tuxedo Festival Shopping Center
Business Wire - Mon Aug 25, 3:15PM CDT
AmREIT, Inc., announced today that it has completed the acquisition of Tuxedo Festival Shopping Center, a 54,643 square foot shopping center located on 3.96 acres in the Buckhead submarket of Atlanta, Georgia.
AMRE: 26.50 (+0.04)

Regency Touches New 52-Week High on Solid Second Quarter Performance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 18, 10:20AM CDT
Shares of Regency Centers (REG) reached a 52-week high of $57.14 during the trading session on Friday, Aug 15, after gaining momentum on solid second-quarter 2014 results.
JLL: 139.47 (-0.44), AMRE: 26.50 (+0.04), CUZ: 12.85 (-0.02), REG: 61.54 (-0.36)

Regency Q2 FFO Beats on Higher Revenues, Raises Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 07, 9:40AM CDT
Higher revenue growth kept Regency Centers Corporation's (REG) winning streak going, with a positive earnings surprise of around 6.0% in second-quarter 2014.
GGP: 25.55 (-0.22), AMRE: 26.50 (+0.04), REG: 61.54 (-0.36), MCO: 98.95 (-0.04)

AmREIT Reports Second Quarter Results and Declares September 2014 Dividend
Business Wire - Tue Jul 29, 3:07PM CDT
AmREIT, Inc. (NYSE: AMRE) ("AmREIT" or the "Company"

today announced financial results for the second quarter ended June 30, 2014 and declared dividends for the third quarter ending September 30, 2014.
AMRE: 26.50 (+0.04)

AmREIT to Explore Strategic Alternatives
Business Wire - Tue Jul 29, 3:06PM CDT
AmREIT, Inc. (NYSE: AMRE) today announced that its Board of Directors has determined to explore strategic alternatives to enhance stockholder value. During this process, the Company will continue to pursue its existing business plan. AmREIT also announced that after a comprehensive review and consultation with its advisors, its Board has rejected the previously announced unsolicited and conditional proposal by Regency Centers Corporation (NYSE: REG) to acquire AmREIT for $22.00 per share.
AMRE: 26.50 (+0.04), REG: 61.54 (-0.36)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Hims & Hers Faces FTC Heat: Investor Class Action Looms

Trouble Is Brewing for Hims & Hers Investors This isn't your typical quiet stroll through the park when it comes to Hims & Hers Health, Inc. (NYSE: HIMS). We're talking about a full-blown legal showdown that's unfolding faster than you can say 'telehealth scandal.' October 25, 2026, saw the kind of announcement that makes seasoned investors' hearts skip a beat if they've...

China's 15th Plan: Key Moves in the Capital Markets

Riding the Waves of Reform in China The winds of change are blowing through China's capital markets, and Guosen Securities is putting a stake in the ground with bold priorities for the 15th Five-Year Plan. As far as I'm concerned, the headlines here are thick with implications for anyone eyeing a piece of China's economic pie from 2026–2030. The Pillars of Stability and...

CStone's CS2009: A Leap in Cancer Treatment Validated

CStone's Game-Changer: CS2009 in the Spotlight CStone Pharmaceuticals just pulled a rabbit out of a hat at the ESMO 2026 Congress, showcasing the clinical might of their CS2009. This ain't just another hype train, folks. We're talking about a trispecific antibody targeting PD-1, VEGF, and CTLA-4. With data rolled out from over 300 patients, this compound promises a...

NOTHING NINE's Global Ambitions: Paris Show's Impact

Paris: Stage or Launchpad? You’d think walking that catwalk in Paris is the holy grail—fashion's own illustrious red carpet. But when you're Chloe, founder of NOTHING NINE, the real hustle kicks off once the lights dim. On 29th September 2026, this designer brand strutted its stuff at one of the grandest venues, Les Invalides, part of the prestigious Paris Fashion...

Ambient AI Shows Promise for Boosting Cancer Care Efficiency

Study Points to Ambient AI's Promise in Oncology Some days, the world of cancer care is a real beast to tackle. But today, we've got a glimpse into how technology, and specifically ambient AI, might just help slay some of the burdens that these healthcare warriors face daily. The Florida Cancer Specialists & Research Institute (FCS) joined hands to dive into how this tech...

Superteam Wheels Rides Into Spain with RACEIT Deal

Rolling Out the Red Carpet for Spanish Cyclists Think of it as the pedal-powered bridge from wherever Superteam Wheels calls home to the sunny streets of Spain. If you're in the cycling game, this new partnership between Superteam Wheels and COMERTECH RACEIT, S.L., better known as RACEIT, is drawing a line in the sand—or perhaps on the asphalt—across Europe. Starting...

Zinzino Eyes European Market With New Botanical Line

Zinzino's Strategic Play in Europe's Wellness Market There's a new player on the European wellness block, and it's Zinzino's latest concoction of fermented botanical supplements. This isn't just your run-of-the-mill vitamin shop stock; we're talking about a lineup crafted for distinct parts of the day, reflecting an evolving consumer trend. People are looking for tailored...

HCLTech Partners with Rapidus on Semiconductor Future

Making Sense of the HCLTech and Rapidus Collaboration When you're talking about the world of semiconductors, no two words get tossed around more than innovation and speed. Now, with the recent partnership between HCLTech and Rapidus, those words are bound to echo from India to Japan and beyond. We have HCLTech, a stalwart of global technology, teaming up with Rapidus, a...

ASICS and University of Michigan Launch Innovation Lab

Running Innovation Gets a Boost in Ann Arbor On a crisp fall day up in Ann Arbor, ASICS and the University of Michigan have decided it's high time to shake up the world of running product R&D. These two powerhouses just launched the ASICSx Michigan Sport Innovation Center (AMSI), an academic-industry research lab. It's like they're mixing college smarts with business...

Ivonescimab Promises New Hope for Advanced BTC Patients

Shifting the Paradigm in Biliary Tract Cancer Treatment Here's the scoop from the bustling world of oncology: the trial of Ivonescimab plus chemotherapy is stirring waves among experts in advanced biliary tract cancer (BTC). Contrary to the usual drowsy mornings with coffee and market pages, this data from Hong Kong wasn't about Wall Street this time. This trial might...